A former board member of Our Bodies, Ourselves, a nonprofit women’s advocacy group, publicly questioned why industry-funded studies were the only ones that appeared to show no higher risk of blood clots from the Yasmin line of contraceptives, compared to other types of birth control pills on the market.
An entry in the organization’s blog mentions testimony that Pamela Bridgewater presented at a U.S. Food and Drug Administration panel’s December ...
continue reading...